As of Apr 29
| -1.49 / -5.45%|
The 6 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 40.00, with a high estimate of 65.00 and a low estimate of 23.00. The median estimate represents a +54.74% increase from the last price of 25.85.
The current consensus among 8 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since April, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.